News Center
30
2023-08
2023-08-30
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC
18
2022-10
2022-10-18
InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022
08
2022-09
2022-09-08
InxMed Announces First Patient Dosed in Pivotal Phase 2 Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer
30
2022-05
2022-05-30
InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Platinum-Resistant Recurrent Ovarian Cancer at ASCO 2022
09
2022-05
2022-05-09
InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers
14
2022-04
2022-04-14
InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer
Previous
1
2
…
4
Next

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us:
CopyRight © 2022 InxMed All Rights Reserved.